Evidence map›Paper›PMID 36017024›Full record

Trial reportContrast media & molecular imaging2022

Multiradiographic Diagnosis of Primary Hepatocellular Carcinoma and Evaluation of Its Postoperative Observation after Interventional Treatment.

Ning Tang, Jing Zhu, Ying Zeng, Xiao Zhang, Jian Zhou

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Contrast media & molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ning TangDepartment of Radiology, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China.
Jing ZhuDepartment of Radiology, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China.
Ying ZengDepartment of Oncology, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China.
Xiao ZhangDepartment of Radiology, The General Hospital of Western Theater Command, Chengdu, Sichuan 610083, China.
Jian ZhouDepartment of Radiology, Joint Security Forces 945 Hospital, Yaan, Sichuan 610083, China.ORCID 0000-0002-4286-9025
Security Forces Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the focal imaging performance of MRI and CT multiphase dynamic enhancement scan examination in primary liver cancer patients, analyze its clinical diagnostic value, and provide a basis for early diagnosis of the disease. Methods: 236 patients with primary liver cancer admitted to our hospital from May 2019 to November 2021 were randomly divided into two groups, the control group was given MRI multiphase dynamic enhancement scan diagnostic method, and the observation group was given CT scan combined with the MRI diagnostic method. The patients' examination results and pathological examination results were compared and analyzed, and the therapeutic effects of patients in the two groups after interventional treatment were compared. Results: After the imaging and pathological examinations of patients in both groups, it was found that the diagnostic accuracy of patients in the observation group and the therapeutic effect after interventional treatment were significantly better than those in the control group. Conclusions: Compared with CT multiphase dynamic enhancement scan, MRI multiphase dynamic enhancement scan can show multidirectional and multiangle lesions in primary hepatocellular carcinoma patients, with better characteristics of blood supply to hepatocellular carcinoma and a higher accuracy rate.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansMagnetic Resonance ImagingTomography, X-Ray Computed

Identifiers

PMID36017024
PMCPMC9371817
OpenAlexW4289793508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.